KARO BIO

PRESS RELEASE

CHANGE OF THE NUMBER OF SHARES AND VOTES IN KARO BIO

STOCKHOLM, January 31, 2013 - Karo Bio AB (publ) today announced that the company's total number of shares as per January 31, 2013 amounts to 495,947,369 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 108,883,397 shares with preferential right for the company's shareholders that was announced on October 24, 2012.

For further information, please contact:

Per Bengtsson, CEO, mobile +46 734 474 128 or e-mail per.bengtsson@karobio.se
Henrik Palm, CFO, mobile +46 70 540 4014 or e-mail henrik.palm@karobio.se

About Karo Bio

Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases and cancer. An important foundation for the company's activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43 employees and is listed on NASDAQ OMX Stockholm.

Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on January 31, 2013, at 8:30 am CET.

This press release is also available at www.karobio.com and www.newsroom.cision.com